Background and Aim: There are no previous reports describing the prognostic significance of the residual intraductal carcinoma component (carcinoma in situ [CIS]) following preoperative treatment for pancreatic ductal adenocarcinoma (PDAC). The aim of the present study was to investigate the prognostic significance of a minimal residual CIS in cases with complete absence of an invasive component after preoperative treatment for PDAC. Methods: Eighty-one of 594 PDAC patients with preoperative treatment and subsequent surgery in our institute showed remarkable remission in the invasive component, which included 48 patients with the minimal residual invasive component (Min-inv group) and 33 with absence of an invasive component (No-inv group). We assessed the survival of these patients in association with the presence or absence of an invasive component and intraductal CIS.
| INTRODUC TI ON
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease because tumor cells have a tendency to spread to the surroundings and/or distant organs and become systematic disease from an early stage. [1] [2] [3] A solely surgical approach for PDAC is able to potentially cure this disease in few patients. 4, 5 The surgery-alone strategy provides the minimum survival benefit in the majority of patients with localized PDAC (ie, resectable [R] or borderline resectable [BR] stage); 6 thus, multimodal strategies, including surgery plus pre-/ postoperative therapies, have been attempted to improve surgical outcomes in patients with R/BR-PDAC. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In our institute, we conducted a multimodal treatment strategy consisting of surgical resection following preoperative treatment and subsequent postoperative treatment for patients with PDAC. 7, 8 Preoperative therapies have certain possible clinical benefits, [18] [19] [20] [21] [22] including a locoregional effect, early administration of systemic therapy and possible reduction in systemic recurrence after surgery. Histopathological evaluations of resected specimens after preoperative treatment (ie, histopathological response) are one of the indicators to assess the efficacy of preoperative treatment, and the histopathological response has been investigated in association with survival after surgery. Several reports have shown a remarkable response to preoperative therapy for PDAC, indicating a significantly preferable patient prognosis. [11] [12] [13] [14] [15] [16] Pathological complete response (pCR) is recognized as the ultimate form of histopathological response, and previous reports showed that 1.6%-13% of PDAC patients showed pCR to preoperative therapy (the total number of patients with pCR was 44 cases in those studies), 15, 16, [21] [22] [23] pCR is defined as the observation of complete absence of an invasive cancer component in the post-treatment tissue. 24, 25 However, how to interpret the minimal residual intraductal component (CIS, carcinoma in situ) is controversial in relation to the definition of pCR. The recently published Japanese classification first referred to residual CIS after preoperative treatment for PDAC 26 and, in previous reports, patients showing complete remission of the invasive component with minimal residual CIS were usually regarded as having pCR as also shown in the new Japanese classification. 15, 16, 21 Nevertheless, there are no reports clearly showing the significance of residual CIS. In breast cancer, previous investigations for the prognostic significance of residual cancer cells in the intraductal component after preoperative therapy showed controversial results, and interpretation of minimal residual CIS remains undetermined in the definition of pCR. [27] [28] [29] [30] In this context, no report has addressed whether pCR applies to cases of minimal residual CIS in the preoperative treatment strategy for PDAC. The clinical significance of minimal residual CIS remains unclear from the prognostic standpoint, whereas a few reports have indicated that the prognosis of patients with the minimal residual invasive component was significantly worse than that of patients showing complete absence of an invasive component in post-treatment tissues after preoperative treatment for PDAC. 15, 16, 21 Therefore, we conducted the present study with the aim of investigating the clinical significance of minimal residual CIS in patients with the absence of an invasive component with reference to the prognostic impact of the minimal residual invasive component in a resected specimen after preoperative chemoradiation therapy for R/BR-PDAC. From the prognostic viewpoint, we evaluated whether it is appropriate that patients with residual PDAC cells in the intraductal component only are classified as having pCR status.
| ME THODS

| Patients
We retrospectively investigated all patients with histologically confirmed PDAC who received an R0 resection following preoperative therapy in our institute from January 2003 to December 2016, and 594 patients were included in this study. Our main strategy for PDAC was not changed during this 14-year period. 7, 8 Patients with PDAC growing outside the pancreas but not into nearby major blood vessels (T3 stage of UICC 7th edition including the R/ BR stage of NCCN classification ver. 1, 2019) are usually recommended to undergo preoperative chemoradiation therapy (CRT, chemotherapy and radiation as conventional external-beam radiotherapy) for 2-3 months before surgery.
| Preoperative therapy
All patients included in the present study received preoperative therapy. During the observation period, several preoperative therapies were used according to the relevant clinical studies.
CRT was mainly used, and chemotherapy regimens were selected at our discretion, mainly depending on the national availability of chemo-drugs. In the first stage, patients were treated by single gemcitabine agent plus radiation. 7 After that, gemcitabinebased combination regimens (gemcitabine/nab-paclitaxel or gemcitabine/S-1) concomitant with radiation therapy were often used. 8, 10 Patients unsuitable for gemcitabine therapy or for radiation therapy were treated with single S-1 agent plus radiation or with gemcitabine-based combination chemotherapy omitting radiation therapy. All of these patients provided written informed consent for participation. 
| Surgery
Computed tomography (CT) or magnetic resonance imaging (MRI) was carried out to judge the resectability of PDAC within the 4 weeks before surgery. Patients who proceeded to surgery underwent pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy as determined by the location and extent of the tumor. Vascular resections were done if involvement of the superior mesenteric vein, portal vein, celiac axis, or hepatic artery was substantial. Vascular reconstruction was preferentially carried out by primary repair. Patch venous repair or interposition grafting was used only when primary repair was not feasible.
| Pathological examination
Pathological examinations were carried out as previously described. 2 Human PDAC samples were obtained with institutional review board approval and fixed in 10% formalin for 48 hours, embedded in paraffin, the specimen cut into 3-4 mm width and sectioned into 3.5-μm slices. Formalin-fixed, paraffin-embedded tissue sections that included PDAC were deparaffinized, hydrated, and stained with hematoxylin and eosin. These samples were adequately evaluated and diagnosed by expert pathologists in our institute, and the effect of preoperative therapy was estimated. In this study, we divided the patients into groups based on two components: the invasive com- 
| Adjuvant chemotherapy and follow up
We carried out liver perfusion chemotherapy (LPC) through the portal vein followed by surgery, as reported previously. 7 All patients received LPC from the first day after surgery if their condition allowed it, and the perfusion was continued for 4 weeks in the hospital.
After discharge from the hospital, patients were highly encouraged to undergo systemic adjuvant chemotherapy. From 2003 to 2011, patients were mainly treated with gemcitabine, based on the results of the CONKO-001 study. 4, 31 Subsequently, S-1 was used as an adjuvant agent, according to the results of the JASPAC-001 study. 5 Follow-up observations were carried out as described previously. 8 To investigate recurrence, three types of examination were carried out every 3-4 months: a routine physical examination; laboratory tests, including the analysis of the serum level of CA19-9 (tumor marker); and radiological imaging, including chest and abdominal CT (or MRI). Date of recurrence was defined as the date on which the investigator detected recurrence on an image or in a biopsy specimen.
The last follow-up date was June 2018, and the median observation time after initial diagnosis of patients was 39.1 months.
| Evaluation of clinicopathological features
We investigated various preoperative variables, including patient characteristics, tumor factors and treatment factors ( Table 1) . We collected common patient parameters and all tumor information, including initial findings at the first visit and before surgery (after preoperative therapy), and the pathological diagnoses were estimated using the resected specimens.
| Statistical analysis
Data are expressed as mean ± standard deviation. The chi-squared test and Fisher's exact test were used for comparing categorical variables, as appropriate. A Kaplan-Meier analysis and log-rank test were used to construct survival curves and to evaluate differences in univariate analysis. Logistic regression was carried out for both the multivariate analysis and the partition analysis of the detected factors. All analyses were done using the JMP 13 software program (SAS Institute. P values <.05). 32
| Ethical considerations
This study was carried out at Osaka International Cancer Institute, Japan, and was approved by the ethics committee of our institution (no. 18195). There was no significant difference in the comparison of clinicopathological parameters of the two cohorts, except for age and rate of administration of adjuvant systemic chemotherapy (Table 2 ). Average patient age was significantly lower and the rate of giving systemic chemo-drugs as adjuvant therapy was significantly higher in the Min-inv group than in the No-inv group.
| RE SULTS
| Tumor regression with preoperative chemoradiation therapies
| Absence of tumor cells in the invasive component after preoperative therapy indicated significantly better prognosis
Tumor size, resectability and value of the tumor marker did not differ between the cohorts at the initial visit. There was no difference in OS between patients with initial R-PDAC and patients with initial BR-PDAC (5-year survival rate of R-PDAC 73%, BR-PDAC 81%, P value .96) in this study that investigated patients who showed remarkable regression with preoperative therapies.
Type of preoperative therapy did not tend to change the rate of absence of cancer cells in the invasive component, and the value of the tumor marker after preoperative therapy did not distin- 
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Presence More specifically, the 5-year survival rates of the patients who received postoperative LPC and those who did not were 76% and 79%, respectively (P = .36), and those of patients who received systemic adjuvant chemotherapy and those who did not were 68% and 84%, respectively (P = .14).
| Presence of CIS did not affect the prognosis of patients with no viable cells in the invasive component
To 5-year RFS: 92% and 73%, respectively, P = .51). Comparison of the clinicopathological parameters did not detect any significant difference between these groups (Table 3 ). were not. [33] [34] [35] In this context, the pCR cases with absence of CIS might originate from tumors that were not originally accompanied Recurrence in pCR cases is an important problem to be addressed. In the current study, four of 33 pCR cases experienced tumor recurrence after surgery following preoperative treatment, and lung recurrences were observed in all of those cases. Several similar cases of PDAC with pCR were previously reported during this period. 15, 21 These clinical observations suggest that even pCR does not guarantee "cure" of PDAC and that pCR of PDAC should not signify the end of treatment. Although pCR indicates the maximum grade of response to preoperative treatment and the complete absence of tumor cells in the locoregional area, we should be wary of subclinical distant tumor disseminations in patients with PDAC. 36, 37 In this regard, postoperative adjuvant systemic chemotherapy may have prognostic significance even in pCR cases, although there has been no report addressing this concern. Indeed, in the current study, three of four pCR patients who developed recurrence after surgery did not receive systemic adjuvant chemotherapy, although our results failed to show a significant impact of adjuvant treatment on OS possibly because of the inherent biases regarding delivery of the adjuvant treatment due to the retrospective nature of this study. In contrast, in reports of rectal cancer, giving adjuvant chemotherapy was associated with improved OS in patients with pCR after neoadjuvant treatment. 38 Further study with a larger patient cohort is required to assess the significance of postoperative adjuvant systemic chemotherapy in pCR cases after preoperative treatment.
| D ISCUSS I ON
The present study has some limitations, including its retrospective nature and the lack of unity in preoperative therapy. Results of this study can be compared with other studies only when patients receive similar perioperative treatments to those carried out in the present study. For further validation of whether our hypothesis concerning pCR is correct in other treatment situations, we must prospectively accumulate pCR data in a multicenter method, referring to whether the cases involve residual cancer cells in the intraductal component.
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